Published Study Demonstrates the Association Between Immunovaccine’s Proprietary Immune-targeted Delivery Technology

Immunovaccine (TSX:IMV) a clinical stage immuno-oncology company, announced the publication of a preclinical study using magnetic resource imaging (MRI) to follow cancer peptide uptake in tumor models, and to correlate this immune activation to the resulting anti-cancer T cell activity.
As quoted in the press release:

The Journal of Biomedical Science study, titled “Unique Depot Formed by an Oil Based Vaccine Facilitates Active Antigen Uptake and Provides Effective Tumour Control,” compared the mechanism of action (MOA) of Immunovaccine’s platform for immunotherapeutic stimulation with other technologies. In the study, published on January 27, 2018, researchers tracked how the cancer peptides were trafficked from the injection site to immunogenic activation in the lymph nodes.

Click here to read the full press release.